Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21542/gcsp.2021.11 http://scihub22266oqcxt.onion/10.21542/gcsp.2021.11 34285902!8272412!34285902     free     free     free       Glob+Cardiol+Sci+Pract 2021 ; 2021 (2): e202111 Nephropedia Template TP {{tp|p=34285902|t=2021. Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre |pdf=|usr=}}{{34285902}} gab.com Text Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre JO: Glob Cardiol Sci Pract http://www.kidney.de/pget.php?&tw=1&pmid=34285902 #FOAvip In this article we summarize the cardiovascular adverse events that were observed in three patients during their treatment for COVID-19 and discuss their association with lopinavir/ ritonavir (LPV/r) and hydroxychloroquine (HCQ). The cases were reported to our regional pharmacovigilance centre in April 2020. All three patients were above 75 years in age, male and multimorbid, and had been hospitalized for treatment of COVID-19. As part of their treatment, all of them received a very strictly monitored off-label therapy with LPV/r and HCQ, for which they had given their prior, written, informed consent. In one patient, erythromycin was also administered. All three patients developed a significant QTc time prolongation during or shortly after therapy with the above drugs. On account of this, the treatment had to be discontinued early in each case and QTc time recovered in all three patients. Twit Text FOAVip Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre ????Glob Cardiol Sci Pract http://www.kidney.de/pget.php?&tw=1&pmid=34285902 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34285902 #FOAvip English Wikipedia <ref>{{Cite pmid|34285902}}</ref> Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre #MMPMID34285902 Istampoulouoglou I; Zimmermanns B; Grandinetti T; Marzolini C; Harings-Kaim A; Koechlin-Lemke S; Scholz I; Bassetti S; Leuppi-Taegtmeyer AB Glob Cardiol Sci Pract 2021[Jun]; 2021 (2): e202111 PMID34285902show ga In this article we summarize the cardiovascular adverse events that were observed in three patients during their treatment for COVID-19 and discuss their association with lopinavir/ ritonavir (LPV/r) and hydroxychloroquine (HCQ). The cases were reported to our regional pharmacovigilance centre in April 2020. All three patients were above 75 years in age, male and multimorbid, and had been hospitalized for treatment of COVID-19. As part of their treatment, all of them received a very strictly monitored off-label therapy with LPV/r and HCQ, for which they had given their prior, written, informed consent. In one patient, erythromycin was also administered. All three patients developed a significant QTc time prolongation during or shortly after therapy with the above drugs. On account of this, the treatment had to be discontinued early in each case and QTc time recovered in all three patients. ?Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychlor(epmc).pdf DeepDyve Pubget Overpricing